On September 21, INNOVENT BIO rose 3.62% in regular trading, trading at HK$100.2 per share, with turnover of HK$209 million. The gain was driven by a combination of robust first-half earnings and catalysts from the World Conference on Lung Cancer (WCLC).

The company reported H1 total revenue of RMB 8.618 billion, up 44.8% year-over-year, with product revenue reaching RMB 8.201 billion, up 56.7%. IFRS net profit hit RMB 1.253 billion, a 50.2% increase, already surpassing the full-year level of the prior year. Growth was co-driven by oncology and comprehensive product lines, with mazdutide, PCSK9, and IGF-1R maintaining rapid volume growth. Management also issued a 2030 total revenue target of RMB 35-40 billion for the first time.

Meanwhile, the WCLC held September 12-15 featured multiple Chinese innovative drug clinical readouts, reinforcing global competitiveness. Brokerages including CLSA, Daiwa, Nomura, and Goldman Sachs have raised target prices, with CLSA setting the highest at HK$146.1. JPMorgan recently increased its stake by approximately 2.36 million shares. Institutions broadly noted that post-pullback valuations present attractive entry points for the innovative drug sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)